Kynos Therapeutics, an Edinburgh, Scotland, UK-based immune-metabolic firm, raised GBP£9M in funding.
The £6.5m fairness spherical was led by Epidarex Capital, joined by Ip Group and Scottish Enterprise. Kynos has additionally been awarded £2.5m by means of an Innovate Uk Grant. Following the financing Dr Elizabeth Roper, Companion at Epidarex Capital, and Dr Tassos Konstantinou, Funding Supervisor, Life Sciences at IP Group plc, have joined Kynos’s board of administrators.
The corporate intends to make use of the funds to develop operations and its growth efforts, particularly to finance its lead KMO inhibitor (KMOi) programme by means of Section 1 medical trials and to progress its progressive pipeline of first-in-class KMOi throughout key indications in irritation, immunity and metabolism.
Kynos Therapeutics is an immune-metabolic firm with world-leading experience within the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology. A spin-out from the College of Edinburgh, the corporate has a pipeline of KMO inhibitors throughout key indications in irritation, immunity and metabolism, which was initially co-developed by means of a collaboration between GSK and the College of Edinburgh and is now solely licensed to Kynos.
KMO performs a significant function within the management of irritation and metabolism, contributing to the regulation of the immune system. It’s a mitochondrial enzyme that converts kynurenine into biologically energetic 3HK that damages cells. Blocking KMO reduces 3HK, defending in opposition to tissue injury. Kynos’s pipeline is concentrated on three key areas: in vital sickness post-surgery; in circumstances pushed by irritation; and in cancers the place irritation is stopping the immune system from preventing again.
Kynos’s core founding crew are main specialists in KMO biology and medicinal chemistry with medical, translational and drug discovery expertise: CEO Damian J Mole (Professor of Surgical procedure and MRC Senior Scientific Fellow, the College of Edinburgh Centre for Irritation Analysis; and CSO Scott Webster (Professor of Medicines Discovery, Centre for Cardiovascular Science, College of Edinburgh). The trade engagement and launch of the spin-out firm have been supported by Edinburgh Improvements, the College of Edinburgh’s commercialisation service.